Description

Bavituximab CAS NO 648904-28-3 is a chimeric monoclonal antibody designed to target phosphatidylserine, a lipid component that becomes exposed on the surface of tumor blood vessels and virus-infected cells. This targeted mechanism makes it a critical investigational agent for disrupting the tumor microenvironment and modulating immune responses. It is primarily utilized by pharmaceutical researchers and developers in the fields of oncology and antiviral therapeutics for clinical development and advanced preclinical studies.

Application

• Oncology Research: Investigational use in targeting tumor vasculature and inducing anti-cancer immune responses in various solid tumor models.
• Antiviral Therapeutics Development: Research into treatments for viral infections by targeting virus-infected host cells.
• Immunotherapy Combinations: Evaluation in combination with other immunotherapeutic agents, such as checkpoint inhibitors, to enhance efficacy.
• Preclinical & Clinical Trials: Serves as a key active pharmaceutical ingredient (API) in formulation studies for Phase I-III clinical trials.
• Biomarker & Mechanism of Action Studies: Used in research to understand phosphatidylserine exposure and its role in disease pathology.
• Drug Conjugate Development: Potential candidate as a targeting moiety for antibody-drug conjugates (ADCs) in targeted cancer therapy.

Basic Information

Product Name	Bavituximab
CAS No.	648904-28-3
Molecular Formula	Contact for details
Molecular Weight	Contact for details
Synonyms	3G4; Chimeric 3G4 Antibody; Anti-Phosphatidylserine Monoclonal Antibody (chimeric, mouse/human); Bavituximab (USAN); Tarvacin (previous code name); Immunoglobulin G1, anti-(human phosphatidylserine) (mouse-mouse monoclonal 3G4 γ1-chain), disulfide with mouse-mouse monoclonal 3G4 κ-chain, dimer
EINECS	Contact for details

Quality Control

Our Bavituximab is manufactured under strict quality systems suitable for research and preclinical applications. Each batch is subjected to a comprehensive suite of analytical tests to ensure identity, purity, potency, and consistency. Certificates of Analysis (COA) detailing specifications such as purity (by SEC-HPLC and CE-SDS), endotoxin levels, sterility, and binding activity are provided to support your regulatory and development needs.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store frozen at -20°C to -80°C. Avoid repeated freeze-thaw cycles. The product is hygroscopic (moisture-sensitive); ensure containers are sealed under controlled atmospheric conditions where applicable. Allow to equilibrate to room temperature before opening to prevent condensation.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or clear to slightly opalescent solution
Identification (SEC-HPLC / CE-SDS)	Conforms to reference standard
Purity (Monomer by SEC-HPLC)	≥ 95.0%
Protein Concentration	As per COA
Endotoxin	< 1.0 EU/mg
Sterility	Sterile (where applicable)
Binding Activity (ELISA / Flow Cytometry)	Conforms to reference standard

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.